Latest Jon Leibowitz Stories
The federal government, consumers, and insurance companies pay an extra $3.5 billion a year for prescription drugs because brand-name companies pay generic producers to stay out of the drug market.
The federal government has cut off the Internet connection of a company charged with aiding criminals in posting a "witches' brew" of horrid subject matter online.
The head of the US Federal Trade Commission said on Monday that companies who track consumer behavior on the Web for targeted advertising without proper consent are near their "last chance" to self-regulate.
Federal regulators said on Thursday they were retooling recommendations for how websites should collect, save and share information about users, extending them to Internet service providers and mobile users.
By Susan Heavey WASHINGTON (Reuters) - Congress should act to protect generic drugmakers from brand-name company tactics that thwart competition and keep cheaper medicines from U.S. consumers, a generic manufacturer said on Thursday.
By Peter Kaplan WASHINGTON (Reuters) - The U.S. Supreme Court on Monday dealt a setback to U.S. antitrust authorities, refusing to consider their appeal to reinstate charges that drug maker Schering-Plough illegally paid generic competitors to stay out of the market.
WASHINGTON (Reuters) - An investigation by U.S. antitrust authorities found no evidence that oil companies illegally manipulated gasoline prices or constrained oil refining operations last year, the Federal Trade Commission said on Monday.
Brand-name drug makers are striking more deals with generic rivals to restrict the introduction of cheaper generic drugs, antitrust authorities said on Monday.
By Peter Kaplan WASHINGTON (Reuters) - Brand-name drug makers are striking more deals with generic rivals to restrict the introduction of cheaper generic drugs, antitrust authorities said on Monday.